FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+10.82%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.5B
AUM Growth
+$2.5B
(+14%)
Cap. Flow
+$160M
Cap. Flow
% of AUM
6.41%
Top 10 Holdings %
Top 10 Hldgs %
67.82%
Holding
55
New
8
Increased
16
Reduced
5
Closed
6
Top Buys
| 1 |
Zai Lab
ZLAB
|
$33.5M |
| 2 |
Aura Biosciences
AURA
|
$31.9M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
$22.6M |
| 4 |
Evolus
EOLS
|
$22.4M |
| 5 |
Akero Therapeutics
AKRO
|
$19.6M |
Top Sells
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$36M |
| 2 |
Soleno Therapeutics
SLNO
|
$35.7M |
| 3 |
Merus
MRUS
|
$15.7M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$7.81M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$7.2M |
Sector Composition
| 1 | Healthcare | 99.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$3.71B
| $346M | 13.83% | 6,795,121 | – | – |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $320M | 12.8% | 3,383,950 -73,900 | -2% | -$6.99M |
|
3
NewAmsterdam Pharma
NAMS
$2.71B
| $301M | 12.03% | 16,607,074 +490,656 | +3% | +$8.89M |
|
4
BridgeBio Pharma
BBIO
$9.89B
| $164M | 6.56% | 3,800,457 | – | – |
|
5
Arcutis Biotherapeutics
ARQT
$1.86B
| $138M | 5.54% | 9,874,511 +1,089,227 | +12% | +$15.3M |
|
|
6
Phathom Pharmaceuticals
PHAT
$864M
| $120M | 4.78% | 12,466,489 +2,357,210 | +23% | +$22.6M |
|
7
Krystal Biotech
KRYS
$4.27B
| $94.6M | 3.78% | 688,460 | – | – |
|
8
Disc Medicine
IRON
$2.07B
| $87.6M | 3.5% | 1,654,834 -100,000 | -6% | -$5.3M |
|
|
MBX
9
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $68.3M | 2.73% | 5,985,347 | – | – |
|
10
Tarsus Pharmaceuticals
TARS
$2.47B
| $56.6M | 2.26% | 1,397,527 | – | – |
|
11
Trevi Therapeutics
TRVI
$883M
| $56.1M | 2.24% | 10,259,409 | – | – |
|
|
MAZE
12
Maze Therapeutics, Inc. Common Stock
MAZE
$635M
| $56M | 2.24% | 4,567,275 +438,274 | +11% | +$5.38M |
|
13
KalVista Pharmaceuticals
KALV
$678M
| $55.3M | 2.21% | 4,887,867 | – | – |
|
|
14
Zai Lab
ZLAB
$3.68B
| $45.7M | 1.83% | 1,308,138 +958,138 | +274% | +$33.5M |
|
15
Agios Pharmaceuticals
AGIO
$2.19B
| $42.6M | 1.7% | 1,279,754 +209,900 | +20% | +$6.98M |
|
16
Revolution Medicines
RVMD
$7.1B
| $36.7M | 1.47% | 997,455 | – | – |
|
17
Ultragenyx Pharmaceutical
RARE
$2.89B
| $35.8M | 1.43% | 983,715 +325,000 | +49% | +$11.8M |
|
|
18
Aura Biosciences
AURA
$389M
| $31.9M | 1.28% | +5,100,000 | New | +$31.9M |
|
19
Erasca
ERAS
$445M
| $28.9M | 1.15% | 22,729,436 +153,585 | +0.7% | +$195K |
|
20
Alkermes
ALKS
$4.78B
| $28.6M | 1.14% | 1,000,647 +399,518 | +66% | +$11.4M |
|
21
Savara
SVRA
$567M
| $26.1M | 1.05% | 11,462,301 | – | – |
|
|
MREO
22
Mereo BioPharma
MREO
$272M
| $25.6M | 1.02% | 9,440,112 +1,620,249 | +21% | +$4.39M |
|
23
Ascendis Pharma
ASND
$11.8B
| $23M | 0.92% | 133,333 | – | – |
|
|
24
Evolus
EOLS
$494M
| $22.4M | 0.9% | +2,435,550 | New | +$22.4M |
|
25
HilleVax
HLVX
$105M
| $21.1M | 0.84% | 10,617,062 | – | – |
|